Neuphoria Therapeutics Inc.
NEUP
$4.19
$0.020.48%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 211,558.11% | 4,347.65% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 35,535.97% | 847.13% | -- |
| Cost of Revenue | 38.45% | -1,900,900.00% | -208.32% | -63.96% | -449.62% |
| Gross Profit | 468.29% | 17,550,300.00% | 768.99% | 104.84% | 497.58% |
| SG&A Expenses | 2.73% | -8.27% | -11.68% | -28.48% | -21.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.77% | -7.41% | -10.98% | -27.90% | -27.59% |
| Operating Income | 81.67% | 95.34% | 97.41% | 31.27% | 27.74% |
| Income Before Tax | 10.60% | 94.62% | 130.74% | 59.69% | 48.78% |
| Income Tax Expenses | -100.87% | -436.54% | -167.46% | 0.72% | -33.17% |
| Earnings from Continuing Operations | 12.50% | 97.61% | 132.19% | 60.09% | 49.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.50% | 97.61% | 132.19% | 60.09% | 49.32% |
| EBIT | 81.67% | 95.34% | 97.41% | 31.27% | 27.74% |
| EBITDA | 85.22% | 99.03% | 101.10% | 32.29% | 28.68% |
| EPS Basic | 68.93% | 100.22% | 116.52% | -51.00% | -85,220.42% |
| Normalized Basic EPS | 72.84% | 97.33% | 80.54% | -103.45% | -106,700.00% |
| EPS Diluted | 68.92% | 100.21% | 116.50% | -51.00% | -85,222.54% |
| Normalized Diluted EPS | 72.84% | 97.33% | 80.54% | -103.45% | -106,700.00% |
| Average Basic Shares Outstanding | 89.02% | -99.57% | -99.83% | -99.90% | -99.93% |
| Average Diluted Shares Outstanding | 89.02% | -99.57% | -99.83% | -99.90% | -99.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |